Amarin Corporation plc
AMRN · Price history
Price at last available close
$12.75
−$0.50 (-3.77%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Amarin Corporation plc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only.
How they make money
Amarin is a pharmaceutical company that generates revenue primarily through the commercialization and sale of its proprietary cardiovascular therapeutic, VASCEPA (icosapent ethyl). The company operates by supplying the drug to wholesalers and distributors in the United States and through collaboration agreements with third-party partners in international markets, who compensate Amarin for the product supply.
Products & services
VASCEPA (icosapent ethyl) is a prescription-only, single-molecule drug product consisting of the omega-3 fatty acid, eicosapentaenoic acid, indicated for cardiovascular risk reduction.
Brands & revenue mix
The company's primary cardiovascular therapeutic product.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
VASCEPA is sold principally to a limited number of major wholesalers, regional wholesalers, and mail-order pharmacy providers, creating a concentration of customers as of the fiscal year ended 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production and supply of its active pharmaceutical ingredient and finished drug product.Source
Strengths
- Proprietary cardiovascular therapeutic VASCEPASource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 42.0% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
24
Poor
Financial Strength
33
Business Quality / Moat
14
Management
40
Growth Quality
6
Risk / Durability
17
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
20
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
21/100
Building Historical Record
Model Score 21/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for AMRN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving AMRN's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is AMRN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is AMRN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for AMRN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AMRN's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
20
Market Cap
$263.6M
P/E Ratio
-9.1
EPS
$-1.43
52-Week High
$20.90
52-Week Low
$12.96
Beta
0.76
Analyst Target
$2.00
Shares Outstanding
20.7M
Total Revenue
$186.2M
Total Debt
$5.3M
Dividend
No current dividend
Liquidation Value / Share
$21.38
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AMRN
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-1991.6x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on AMRN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary cardiovascular therapeutic VASCEPA.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
- −Dependence on a single product for substantially all revenue.
- −Reliance on third-party manufacturers and suppliers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
23
Sep 8, 2026
Change
+0.1
points
Current Score
24
Oct 1, 2026
Category Changes
AMRN increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
22
Projected Change
-1.4 points
Preliminary comparable-period financial changes suggest decline of approximately 1.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$12.74
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $186.2M | $213.6M | $228.6M | $306.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $108.8M | $92.8M | $147.2M | $141.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $77.4M | $120.9M | $81.4M | $165.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $18.3M | $19.8M | $20.9M | $22.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $83.1M | $115.0M | $152.3M | $199.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $110.7M | $134.8M | $173.2M | $222.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$19.7M | -$33.0M | -$74.2M | -$50.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$33.3M | -$13.9M | -$91.8M | -$56.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $7K | $7K | $8K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$25.6M | -$36.0M | -$77.2M | -$53.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1.6M | $2.8M | $5.0M | $5.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$27.1M | -$38.8M | -$82.2M | -$59.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.43 | $-1.80 | $-4.00 | $-3.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 20.82M | 20.75M | 20.55M | 19.70M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 20.82M | 20.75M | 20.55M | 20.38M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$42.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.40
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-28.4%
Cash Change
-2.9%
Margin Change
+1.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels, net income margin. Pressure indicators included revenue growth, EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 42.0%. EPS declined 41.2%. Cash declined 2.9%. Total debt declined 28.4%. Net income margin improved by 1.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - GeneralNews
What Amarin (AMRN) Said on Its Q3 Earnings Call
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)
Rumor Mill · AMRN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial